Medical Devices

BD reports 2.8% decline in Q1 2023 revenues

Time Stamp: February 3, 2023 7:00 AM
Source Node: 2384707

Republished By Plato

<!–

–>

BD generated $4.55bn base business revenue in Q1 of fiscal year 2023, a 0.4% increase from the previous year. Credit: SKreutz / commons.wikimedia.org.

Becton, Dickinson and Company (BD) has reported a 2.8% decline in revenue to $4.58bn in the first quarter (Q1) of the fiscal year 2023, from $4.71bn in the same quarter of the previous year.

The base business revenue grew by 0.4%, or 5.2% on a currency-neutral basis, for the quarter, reaching $4.55bn compared to $4.53bn in the prior-year quarter.

The company’s GAAP stood at $1.70, while the adjusted diluted EPS was at $2.98.

For the quarter, the BD Medical segment reported $2.15bn in revenues, a 1.6% growth from $2.12bn in the same quarter of the previous year.

This growth is attributed to strong performance in the Medication Delivery Solutions (MDS) and Pharmaceutical Systems (PS) business units.

The BD Life Sciences segment generated $1.3bn revenue, showing a 12.2% decrease from $1.48bn in the prior year’s quarter.

In the BD Interventional segment, $1.129bn revenue was generated, representing a 1.3% increase from the year-ago quarter.

This growth is mainly driven by strong performance in the Peripheral Intervention (PI) business unit.

BD chairman, CEO and president Tom Polen said: “Our strong performance in Q1 reflects the momentum of our BD 2025 strategy, driven by a combination of innovation and continued strong execution.

“Consistent, durable performance in our base business reflects our team’s relentless focus on delivering category-leading products and transformative solutions that are helping our customers deliver quality and more cost-effective care to patients around the world.”

The company concluded the spin-off of its Diabetes Care business into a separate company, dubbed Embecta, on 1 April 2022.

Last month, BD introduced the new third-generation BD Kiestra Total Lab Automation System for microbiology laboratories.

<!– GPT AdSlot 3 for Ad unit 'Verdict/Verdict_In_Article' ### Size: [[670,220]] —

googletag.cmd.push(function() { googletag.display(‘div-gpt-ad-8581390-1’); });

!– End AdSlot 3 –>

SEO Powered Content & PR Distribution. Get Amplified Today.
Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
Source: https://www.medicaldevice-network.com/news/bd-2-8-decline-q1-2023-revenues/

Tags: 000, 1, 2022, 2023, 2025, 70, 98, a, Ad, adjusted, and, April, ARE, around, around the world, At, attributed, Automation, base, basis, BD, business, by, care, ceo, chairman, combination, Commons, company, company's, compared, concluded, continued, cost-effective, credit, Customers, decline, decrease, deliver, delivering, delivery, diabetes, driven, dubbed, durable, Execution, First, Focus, For, from, GAAP, generated, globaldata, grew, Growth, helping, HTTPS, in, Increase, Innovation, intervention, into, introduced, Is, ITS, jpg, lab, laboratories, Life, mainly, medical, medication, microbiology, Momentum, Month, more, of, on, patients, performance, peripheral, Pi, plato, Plato Data Intelligence, PlatoData, president, previous, Prior, Products, Q1, quality, Quarter, reaching, reflects, relentless, reported, Reports, representing, revenue, revenues, Said, same, segment, separate, Share, showing, Size, Solutions, Strategy, strong, Systems, that, The, the world, to, Total, transformative, unit, units, while, WikiMedia, world, year, zephyrnet

Xlera8

BD reports 2.8% decline in Q1 2023 revenues

Republished By Plato

Delta Emulator Brings Game Boy & More To Apple Vision Pro

Active Kubernetes RCE Attack Relies on Known OpenMetadata Vulns

Quest 3’s Latest Update Brought Two Undocumented Features

Xiid SealedTunnel: Unfazed by Yet Another Critical Firewall Vulnerability (CVE-2024-3400) – Tech Startups

Chat with us